- Home
- MIRA vs PMN Comparison
MIRA vs PMN Comparison
Compare MIRA & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- PMN
- Stock Information
- Founded
- MIRA 2020
- PMN 2004
- Country
- MIRA United States
- PMN Canada
- Employees
- MIRA N/A
- PMN N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- MIRA Health Care
- PMN Health Care
- Exchange
- MIRA Nasdaq
- PMN Nasdaq
- Market Cap
- MIRA 20.5M
- PMN 18.8M
- IPO Year
- MIRA 2023
- PMN N/A
- Fundamental
- Price
- MIRA $0.92
- PMN $0.59
- Analyst Decision
- MIRA Strong Buy
- PMN Strong Buy
- Analyst Count
- MIRA 2
- PMN 1
- Target Price
- MIRA $14.00
- PMN $6.00
- AVG Volume (30 Days)
- MIRA 2.9M
- PMN 37.4K
- Earning Date
- MIRA 05-12-2025
- PMN 05-13-2025
- Dividend Yield
- MIRA N/A
- PMN N/A
- EPS Growth
- MIRA N/A
- PMN N/A
- EPS
- MIRA N/A
- PMN 0.11
- Revenue
- MIRA N/A
- PMN N/A
- Revenue This Year
- MIRA N/A
- PMN N/A
- Revenue Next Year
- MIRA N/A
- PMN N/A
- P/E Ratio
- MIRA N/A
- PMN $5.68
- Revenue Growth
- MIRA N/A
- PMN N/A
- 52 Week Low
- MIRA $0.51
- PMN $0.51
- 52 Week High
- MIRA $5.01
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- MIRA 46.88
- PMN 43.65
- Support Level
- MIRA $0.84
- PMN $0.51
- Resistance Level
- MIRA $1.33
- PMN $0.65
- Average True Range (ATR)
- MIRA 0.10
- PMN 0.09
- MACD
- MIRA 0.01
- PMN 0.01
- Stochastic Oscillator
- MIRA 31.83
- PMN 32.58
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.